Press releases

Boston Scientific will participate in the conference on November 7, 2017.

Late-breaking data presented at TCT 2017 with simultaneous publication in the Journal of the American College of Cardiology

“We continue to invest in a deep and innovative portfolio and expand into faster-growing markets," said CEO Mike Mahoney.

Key data presented will include five-year outcomes for the WATCHMAN device as an alternative to long-term warfarin therapy for patients with non-valvular Afib.

CEO Mike Mahoney welcomed Ralls-Morrison as “an accomplished leader with deep expertise in broad-ranging legal matters and enterprise business strategy.”

Acquisition to strengthen company's electrophysiology portfolio

Company will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2017.

HeartLogic is the first and only heart failure diagnostic in an implantable device shown to provide weeks of advance notice of an impending heart failure event.

Data presented demonstrate alert improves heart failure risk prediction

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...